Less than 10% of patients eligible to benefit from GLP-1 drugs including Wegovy can access them, warns the World Health Organization as it issues its first recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for broader and more equitable access to this class of drugs.
Per estimates, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be managed with comprehensive and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant obstacles to widespread access to the treatments that can help people shift substantial weight, explains the agency.
Skinny Jab Shortage
Even in the current most favorable scenario, the manufacturing of these medications might only reach approximately 100 million people – under 10% of the global need, as stated by the health organization.
The guideline encourages governments and firms to widen availability, via strategies including patent sharing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs imitate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so people consume fewer calories.
Individuals typically see weight reduction after several weeks of beginning the once-weekly jabs.
Studies points to users may put most of the weight back on within a year of halting the drug, when their usual appetite come back.
To be overweight or obese elevates your chance for experiencing diseases, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight affects people in all nations and was associated with millions of fatalities worldwide in 2024, per the health agency.
